FDA’s Risk-Based Site Selection Model
FDA’s Risk-Based Site Selection Model Understanding the FDA’s Risk-Based Site Selection Model for GMP Inspections The US Food and Drug Administration (FDA) employs a risk-based site selection model to determine which domestic and foreign pharmaceutical facilities should be inspected each year. This system prioritizes inspections based on product risk, compliance history, and other strategic factors…